Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LGVN Stock Forecast 2025-2026
$1.38
Current Price
$20.64M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LGVN Price Targets
+627.3%
To High Target of $10.00
+610.9%
To Median Target of $9.78
+336.4%
To Low Target of $6.00
LGVN Price Momentum
-2.8%
1 Week Change
-14.3%
1 Month Change
+23.2%
1 Year Change
-20.2%
Year-to-Date Change
-78.5%
From 52W High of $6.40
+78.3%
From 52W Low of $0.77
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Longeveron (LGVN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LGVN and similar high-potential opportunities.
Latest LGVN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, LGVN has a bullish consensus with a median price target of $9.78 (ranging from $6.00 to $10.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.38, the median forecast implies a 610.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 627.3% upside. Conversely, the most conservative target is provided by Michael Okunewitch at Maxim Group, suggesting a 336.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LGVN Analyst Ratings
3
Buy
0
Hold
0
Sell
LGVN Price Target Range
Low
$6.00
Average
$9.78
High
$10.00
Current: $1.38
Latest LGVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LGVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Dec 5, 2024 | Roth MKM | Boobalan Pachaiyappan | Buy | Initiates | $10.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Aug 27, 2024 | Maxim Group | Michael Okunewitch | Buy | Maintains | $6.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jul 29, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| May 17, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Apr 29, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
| Dec 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $6.00 |
| Jun 1, 2023 | EF Hutton | Fozia Ahmed | Buy | Assumes | $12.50 |
| May 16, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $12.50 |
| May 9, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $12.50 |
| Mar 27, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $12.50 |
| Jan 10, 2023 | EF Hutton | Constantine Davides | Buy | Maintains | $12.50 |
| Mar 24, 2022 | Maxim Group | Michael Okunewitch | Buy | Initiates | $14.00 |
| Jan 5, 2022 | EF Hutton | Buy | Initiates | $0.00 |
Longeveron Inc. (LGVN) Competitors
The following stocks are similar to Longeveron based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LGVN
Longeveron
mkt cap
21.16M
Longeveron Inc. (LGVN) Financial Data
Longeveron Inc. has a market capitalization of $20.64M with a P/E ratio of 0.0x. The company generates $2.39M in trailing twelve-month revenue with a 78.8% profit margin.
Revenue growth is +857.1% quarter-over-quarter, while maintaining an operating margin of -710.0% and return on equity of -111.6%.
Valuation Metrics
Market Cap
$20.64M
Enterprise Value
$4.46M
P/E Ratio
0.0x
PEG Ratio
-0.9x
Price/Sales
8.6x
Growth & Margins
Revenue Growth (YoY)
+857.1%
Gross Margin
+72.2%
Operating Margin
-710.0%
Net Margin
+78.8%
EPS Growth
-30.5%
Financial Health
Cash/Price Ratio
+93.7%
Current Ratio
7.6x
Debt/Equity
6.6x
ROE
-111.6%
ROA
-54.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Longeveron Inc. (LGVN) Business Model
About Longeveron Inc.
What They Do
Develops cellular therapies for aging-related conditions.
Business Model
Longeveron Inc. generates revenue by developing and commercializing innovative cellular therapies, particularly its lead product Lomecel-B, which targets conditions like Alzheimer’s and infant heart diseases. The company collaborates with research institutions and healthcare providers to enhance clinical understanding and application of its therapies.
Additional Information
As a biotechnology firm, Longeveron is positioned in a rapidly growing market focused on regenerative medicine. Its research initiatives contribute to advancements in treating life-threatening conditions, making it a key player in addressing significant health challenges and improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
25
CEO
Mr. Mohamed Wa'el Ahmed Hashad M.B.A.
Country
United States
IPO Year
2021
Website
longeveron.comLongeveron Inc. (LGVN) Latest News & Analysis
Latest News
Quick Summary
Longeveron will hold Alzheimer's disease program meetings at the BIO 2025 conference, following positive Phase 2a data published in Nature Medicine.
Why It Matters
Longeveron's Alzheimer’s program and successful Phase 2a results may attract interest, signaling potential growth and investment opportunities in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
11 days ago
Quick Summary
Longeveron Inc. (NASDAQ: LGVN) has been named a Top 40 Semifinalist in the XPRIZE Healthspan competition, receiving a $250,000 award for its stem cell therapy targeting Alzheimer's and HLHS.
Why It Matters
Longeveron's recognition as a Top 40 Semifinalist in the XPRIZE Healthspan competition boosts its credibility and visibility, potentially attracting investors and increasing stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Longeveron Inc. (NASDAQ:LGVN) will hold its Q1 2025 Earnings Conference Call on May 8, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
Why It Matters
Longeveron's Q1 2025 earnings call signals upcoming financial insights and strategic updates, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
14 days ago
Quick Summary
Longeveron reports Q1 2025 financial results; Phase 2 clinical trial is 95% enrolled, with full enrollment anticipated by Q2 2025.
Why It Matters
Longeveron's strong enrollment in a pivotal Phase 2 trial signals potential for positive trial outcomes, which could drive stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
21 days ago
Quick Summary
Longeveron (LGVN) is set to report Q1 2025 financial results and provide a business update on May 8, 2025, after U.S. market close.
Why It Matters
Longeveron's Q1 2025 financial results and business update could significantly influence stock performance and investor sentiment ahead of the announcement.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Longeveron Inc. reported positive Phase 2a results for laromestrocel (Lomecel-Bâ„¢) in treating mild Alzheimer's, showing improved cognitive function and safety, and it holds RMAT designation from the FDA.
Why It Matters
Positive Phase 2a results for Lomecel-Bâ„¢ suggest potential market growth for Longeveron Inc. in Alzheimer's treatment, enhancing investor confidence and interest in biotech innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LGVN Stock
What is Longeveron Inc.'s (LGVN) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Longeveron Inc. (LGVN) has a median price target of $9.78. The highest price target is $10.00 and the lowest is $6.00.
Is LGVN stock a good investment in 2025?
According to current analyst ratings, LGVN has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LGVN stock?
Wall Street analysts predict LGVN stock could reach $9.78 in the next 12 months. This represents a 610.9% increase from the current price of $1.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Longeveron Inc.'s business model?
Longeveron Inc. generates revenue by developing and commercializing innovative cellular therapies, particularly its lead product Lomecel-B, which targets conditions like Alzheimer’s and infant heart diseases. The company collaborates with research institutions and healthcare providers to enhance clinical understanding and application of its therapies.
What is the highest forecasted price for LGVN Longeveron Inc.?
The highest price target for LGVN is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 627.3% increase from the current price of $1.38.
What is the lowest forecasted price for LGVN Longeveron Inc.?
The lowest price target for LGVN is $6.00 from Michael Okunewitch at Maxim Group, which represents a 336.4% increase from the current price of $1.38.
What is the overall LGVN consensus from analysts for Longeveron Inc.?
The overall analyst consensus for LGVN is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.78.
How accurate are LGVN stock price projections?
Stock price projections, including those for Longeveron Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 3:52 AM UTC